NRIX250117P15000
- 1.45
- 0.000.00%
Nurix Therapeutics Newsroom
Piper Sandler Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $35
A Quick Look at Today's Ratings for Nurix Therapeutics(NRIX.US), With a Forecast Between $29 to $35
Nurix Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Nurix Therapeutics (NRIX) Receives a Buy From Barclays
Oppenheimer Reaffirms Their Buy Rating on Nurix Therapeutics (NRIX)
Nurix Therapeutics (NRIX) Receives a Buy From Stifel Nicolaus
Needham Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $29
Optimistic Buy Rating for Nurix Therapeutics' NX-5948 Driven by Strong Efficacy in CLL and Strategic Expansion Plans
Nurix Therapeutics Price Target Maintained With a $29.00/Share by Needham
Nurix Therapeutics Initiated at Outperform by BMO Capital
Nurix Therapeutics Analyst Ratings
BMO Capital Initiates Nurix Therapeutics(NRIX.US) With Buy Rating, Announces Target Price $35
Piper Sandler Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $35
Needham Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $29
Promising Efficacy and Safety of Nurix Therapeutics' NX-5948 Justifies Buy Rating
Nurix Therapeutics Price Target Maintained With a $29.00/Share by Needham
Nurix Therapeutics Analyst Ratings
UBS Initiates Coverage On Nurix Therapeutics With Buy Rating, Announces Price Target of $35
Barclays Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $31
A Quick Look at Today's Ratings for Nurix Therapeutics(NRIX.US), With a Forecast Between $29 to $41